• 5 Smart Ways to Increase Medical Affairs Tenure Without Investing Much

    Panorama by on March 28th, 2017

    As a Medical Advisor for almost seven years in Big Pharma, I know what it feels like when you reach a certain level and nobody can clearly explain to you what is next in your Medical Affairs career. Interestingly, the more I tried to take on new tasks or expand my responsibilities to bring more […]

  • 3 Tools to Help Medical Affairs Professionals Stay Up-To-Date With Important Research

    Panorama by on September 28th, 2016

    When facilitating peer-to-peer interactions between KOLs and prescribing healthcare practitioners, Medical Affairs professionals need to take multiple therapeutic areas into account and adopt an independent view when assessing clinical value. This requires continuous monitoring of the latest scientific data, clinical guidances, and controversies. Moreover, both Medical Affairs executives and field professionals have to quickly respond […]

  • Defining the Value of MSL Teams

    Panorama by and on November 20th, 2015

    About a year ago, Stephen Dodge wrote a thoughtful article about CRM tools for Medical Science Liaisons (MSLs). In the article, Stephen shared the results of a survey to determine MSLs’ opinion of the state-of-the-art CRM tool for their profession. After almost 40 responses, he identified three key issues for MSLs: 98% believed that CRM […]

  • 8 Success Factors of Smart KOL Engagement

    Feature Articles by on August 17th, 2014

    KOLs are an important extension of the pharmaceutical company’s central nervous system. Only a few years ago KOL management in companies was limited to identifying eight to 11 heavyweights in a therapeutic area that involved them in promo events. Now, when more regulatory barriers are built around healthcare practitioners by governments, academic and patient communities, […]

  • Nine Key Elements To Ensure Advisory Board Success

    The relationship between pharmaceutical companies and medical stakeholders will need to evolve thanks to the greater public scrutiny these relationships will now receive under various regulatory changes including the Sunshine Act. Under this intense public scrutiny and demands for greater transparency through financial disclosures, pharma’s engagement with thought leaders will need to significantly transform. As […]

Back to top